From bench to bedside – preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A)
University of Vienna · Max Planck Society · +1 more institution
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
953
total citations
- FWCI
- 24.30
- Percentile
- 100%
- References
- 63
Citations per year
Authors
6Topics & keywords
Topics
Keywords
- Indazole
- Chemistry
- Bench to bedside
- Combinatorial chemistry
- Pharmacology
- Medicinal chemistry
- Medical physics
- Medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.